---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-009173"
form_type: "8-K"
ticker: "PLSH"
cik: "0001552189"
company_name: "PANACEA LIFE SCIENCES HOLDINGS, INC."
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:31:24.278042+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Panacea Life Sciences issues 666K shares to settle $100K note payment

## Summary
- Converted $100,000 note payment to 666,000 shares of common stock on March 5, 2024.
- Previous conversion in Feb 2023: 540,000 shares at $0.25/sh partially repaid the $385K note.
- Original $385K Senior Convertible Note issued Mar 2022 in exchange for 350 Series A Preferred shares.
- Company could not fund $100K cash payment due June 30, 2023; settled via stock conversion.

## SEC filing metadata
- accession: 0001493152-24-009173
- form_type: 8-K
- ticker: PLSH
- cik: 0001552189
- company_name: PANACEA LIFE SCIENCES HOLDINGS, INC.
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1552189/000149315224009173/0001493152-24-009173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1552189/000149315224009173/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-009173
- JSON: https://secwatch.observer/filing/0001493152-24-009173.json
- Plain text: https://secwatch.observer/filing/0001493152-24-009173.txt

## Key facts
- Debt Financings
  PANACEA LIFE SCIENCES HOLDINGS, INC. incurred convertible notes of $385,000 Senior Convertible Note with an institutional investor maturing March 3, 2022 (dated); repayment terms include a Note Payoff Agreement dated February 9, 2023.
  - Instrument: convertible notes
  - Principal: $385,000 Senior Convertible Note
  - Counterparty: an institutional investor
  - Maturity: March 3, 2022 (dated); repayment terms include a Note Payoff Agreement dated February 9, 2023
  - Event: incurrence
  source text: the Investor exchanged 350 shares of the Company’s Series A Preferred Stock, par value $0.0001, for a Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (the “Note”). The parties have agreed that the Company will repay the Note in full pursuant to the terms of a Note Payoff Agreement dated February 9, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1552189/000149315224009173/0001493152-24-009173-index.htm
- Material Agreements
  PANACEA LIFE SCIENCES HOLDINGS, INC. entered into Share Exchange Agreement with institutional investor valued at Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (effective 2022-03-03).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: institutional investor
  - Value: Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended
  - Effective: 2022-03-03
  source text: On March 3, 2022, Panacea Life Sciences Holdings, Inc. (the “Company”) entered into a Share Exchange Agreement with an institutional investor (the “Investor”) pursuant to which the Investor exchanged 350 shares of the Company’s Series A Preferred Stock, par value $0.0001, for a Senior Convertible Note dated March 3, 2022 in the principal amount of $385,000, as amended (the “Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1552189/000149315224009173/0001493152-24-009173-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.